Biomarkers in Neurodegenerative Diseases

University of Minnesota1 site in 1 countryOctober 1, 2019

ConditionsMild Cognitive Impairment (MCI)Alzheimer Disease (AD)Dementia With Lewy Bodies (DLB)Frontotemporal Lobar Degeneration (FTLD)Parkinsons Disease With Dementia (PDD)Transient Epileptic Amnesia (TEA)Temporal Lobe Epilepsy (TLE)Spinocerebellar Ataxias (SCA)HIV Associated Neurocognitive Disorder (HAND)Amyotrophic Lateral Sclerosis (ALS)Primary Lateral Sclerosis (PLS)

Overview

Phase: N/A
Intervention: Not specified
Conditions: Mild Cognitive Impairment (MCI)
Sponsor: University of Minnesota
Locations: 1
Primary Endpoint: Performance on Batteries of Cognitive Tests
Status: Withdrawn
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.

Registry

clinicaltrials.gov

Start Date

October 1, 2019

End Date

October 1, 2025

Last Updated

6 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

University of Minnesota

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Diagnosis of MCI, AD, DLB, FTLD, PDD, TEA, TLE, SCA, HAND, ALS, PLS, or normal control.
•Age 18 or older
•Reliable informant with frequent contact with participant
•Mini Mental State Exam (MMSE) ≥15 AND/OR Clinical Dementia Rating (CDR) less than 2
•Able to undergo extensive psychometric testing

Exclusion Criteria

•Any conditions that could account for cognitive deficits in addition to a neurodegenerative disease, including but not limited to:
•Past or present diagnosis of Korsakoff's syndrome
•Alcohol or substance abuse preceding dementia \& still present within 5 years of onset
•Present untreated vitamin B12 or folate deficiency
•Present untreated hypothyroidism
•Past or present head trauma with persistent deficits
•Present untreated syphilis
•Past or present multiple sclerosis or another neuro-inflammatory disorder
•Past or present vascular or multi-infarct dementia
•Past or present diagnosis of huntington's disease

Outcomes

Primary Outcomes

Performance on Batteries of Cognitive Tests

Time Frame: 2-5 Years

Performance on batteries of cognitive tests as measured by the Modified Autobiographical Memory Interview (MAMI), Stroop Test, CDR-SOB, Spontaneous Speech Test, and the Neuropsychological Battery from the Uniform Data Set.